GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (FRA:BXA0) » Definitions » Ending Cash Position

Lavipharm (FRA:BXA0) Ending Cash Position : €8.69 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lavipharm Ending Cash Position?

Lavipharm's Ending Cash Position for the quarter that ended in Jun. 2024 was €8.69 Mil.

Lavipharm's quarterly Ending Cash Position declined from Jun. 2023 (€14.41 Mil) to Dec. 2023 (€8.44 Mil) but then increased from Dec. 2023 (€8.44 Mil) to Jun. 2024 (€8.69 Mil).

Lavipharm's annual Ending Cash Position increased from Dec. 2021 (€1.64 Mil) to Dec. 2022 (€18.24 Mil) but then declined from Dec. 2022 (€18.24 Mil) to Dec. 2023 (€8.44 Mil).

Lavipharm Ending Cash Position Historical Data

The historical data trend for Lavipharm's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm Ending Cash Position Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 1.73 1.93 1.64 18.24 8.44

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.74 18.24 14.41 8.44 8.69

Lavipharm Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lavipharm's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=18.243+-9.808
=8.44

Lavipharm's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.435+0.253
=8.69

Lavipharm Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Lavipharm's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Lavipharm Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (FRA:BXA0) » Definitions » Ending Cash Position
Comparable Companies
ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124 BOM:500257 NBIX
Traded in Other Exchanges
LAVI:Greece
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Website
http://www.lavipharm.com
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm Headlines

No Headlines